Biomarkers in acute coronary syndromes and their role in diabetic patients

Diabetes and Vascular Disease Research

Volumn 2, Issue 3, 2005, Pages 122-127

  Heeschen, Christopher ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Department of Oncology and Transplantation Medicine ^*  (Germany)

Author keywords

Acute coronary syndrome; Biomarker; Risk stratification; Troponin; Unstable angina

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CREATINE KINASE MB; DALTEPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; IMMUNOGLOBULIN F(AB) FRAGMENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDE DERIVATIVE; PLACEBO; PLACENTAL GROWTH FACTOR; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC VALUE; ELECTROCARDIOGRAM; HEART MUSCLE NECROSIS; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; NEUROIMMUNOLOGY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION; THORAX PAIN; TREATMENT OUTCOME;

EID: 28144444195     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2005.019     Document Type: Review

References (63)

1. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
2. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb 1992;12:647-56.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
4. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524.
5. Mak KH, Moliterno DJ, Granger CB et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:171-9.
6. Granger CB, Califf RM, Young S et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993;21:920-5.
7. Malmberg K, Yusuf S, Gerstein HC et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 2000;102:1014-19.
8. McGuire DK, Emanuelsson H, Granger CB et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J 2000;21:1750-8.
9. Nesto RW, Phillips RT. Silent myocardial ischemia: clinical characteristics, underlying mechanisms, and implications for treatment. Am J Med 1986;81:12-19.
10. Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 2001;58:1533-8.
11. Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation 2000;102:118-22.
12. Klootwijk P, Hamm C. Acute coronary syndromes: diagnosis. Lancet 1999;353:SII10-15.
13. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337:1648-53.
14. Hamm CW, Ravkilde J, Gerhardt W et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992;327:146-50.
15. Ravkilde J, Horder M, Gerhardt W et al. Diagnostic performance and prognostic value of serum troponin T in suspected acute myocardial infarction. Scand J Clin Lab Invest 1993;53:677-85.
16. Wu AH, Abbas SA, Green S et al. Prognostic value of cardiac troponin T in unstable angina pectoris. Am J Cardiol 1995;76:970-2.
17. Ohman EM, Armstrong PW, Christenson et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335:1333-41.
18. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation 1996;93:1651-7.
19. Heeschen C, Goldmann BU, Moeller RH, Hamm CW. Analytical performance and clinical application of a new rapid bedside assay for the detection of serum cardiac troponin I. Clin Chem 1998;44:1925-30.
20. Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999;100:1509-14.
21. Antman EM, Tanasijevic MJ, Thompson B et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9.
22. Galvani M, Ottani F, Ferrini D et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation 1997;95:2053-9.
23. Luscher MS, Thygesen K, Ravkilde J, Heickendorff L. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia. Circulation 1997;96:2578-85.
24. Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 1998;81:1405-10.
25. Ottani F, Galvani M, Nicolini FA et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000;140:917-27.
26. Mizuno K, Miyamoto A, Isojima K et al. A serial observation of coronary thrombi in vivo by a new percutaneous transluminal coronary angioscope. Angiology 1992;43:91-9.
27. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73:418-27.
28. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699-708.
29. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999;354:1757-62.
30. Hamm C, Heeschen C, Goldmann et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999;340:1623-29.
31. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
32. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349-53.
33. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
34. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
35. Morrow DA, Rifai N, Antman EM et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI IIA substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998;31:1460-5.
36. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000;35:1535-42.
37. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
38. Koenig W. Update on C-reactive protein as a risk marker in cardiovascular disease. Kidney Int Suppl 2003;84:58-61.
39. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
40. Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
41. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
42. James SK, Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-81.
43. Luttun A, Tjwa M, Moons L et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40.
44. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991;88:9267-71.
45. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003;1:1356-70.
46. Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): Novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci 2002;979:80-93.
47. Heeschen C, Dimmeler S, Fichtlscherer S et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004;291:435-41.
48. Heeschen C, Dimmeler S, Hamm CW et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-11.
49. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000;342:626-33.
50. Khaliq A, Dunk C, Jiang J et al. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab Invest 1999;79:151-70.
51. Cao Y, Linden P, Shima D, Browne F, Folkman J. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 1996;98:2507-11.
52. Cipollone F, Mezzetti A, Porreca E et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002;106:399-402.
53. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;8:1047-54.
54. Lee Y, Lee WH, Lee SC et al. CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 1999;92:11-16.
55. Garlichs CD, Eskafi S, Raaz D et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001;86:649-55.
56. Prasad KS, Andre P, Yan Y, Phillips DR. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 2003;10:356-61.
57. Varo N, de Lemos JA, Libby P et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003;108:1049-52.
58. Omland T, de Lemos JA, Morrow DA et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002;89:463-5.
59. de Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
60. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40:437-45.
61. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003;108:2987-92.
62. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004;110:3206-12.
63. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767-71.